Ian E. Smith, MD, FRCP, FRCPE
Head of the Breast Unit
Professor of Cancer Medicine
The Royal Marsden Hospital
Institute of Cancer Research
London, United Kingdom
2013-2014 BCRF Project:
(The Estée Lauder Companies Brands Award in Honor of Elizabeth Hurley)
Co-Investigator: Mitch Dowsett, PhD, BSc, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
Drs. Smith and Dowsett demonstrated in a retrospective study that there are significant differences in the expression of four estrogen-regulated genes (ERG) during the menstrual cycle. This could affect the interpretation of molecular profiling tests in premenopausal women and have the potential to be used as a test of endocrine responsiveness. This team recently extended their gene expression assays on a larger set of ERGs using the nCounter Analysis System (Nanostring) in the same retrospective samples to determine whether (1) other ERGs and/or proliferation genes showed more dynamic differences across the menstrual cycle and (2) if these gene expression differences occurred at a different periodicity. Preliminary analysis of this data from this new technology has confirmed the team’s previous findings. Detailed statistical analyses are underway to determine the relevance of the other genes and to refine the timing of this team’s pre-defined “windows” of the menstrual cycle. Drs. Dowsett and Smith will test the validity their findings from the retrospective study in both samples being collected from their own UK-based prospective study (MenCER) and in samples received from their collaboration with the study led by fellow BCRF grantee Dr. Richard Love on a Vietnamese study of the impact of oophorectomy (removal of the ovaries) prior to surgery for breast cancer. In a secondary project, Drs. Dowsett and Smith will examine the potential use of RNA extracts from lymph nodes for assessing ER and/or HER2 status where no invasive primary tissue is available; collection of samples for this study is now complete and gene expression analyses are commencing.
Ian Smith is Professor of Cancer Medicine at The Royal Marsden Hospital and Institute of Cancer Research, London, UK He is also Head of the Breast Unit at The Royal Marsden and was Medical Director there from 2000 to 2003
His initial medical training was in Edinburgh and then he came to the Royal Marsden, London for specialist training in cancer medicine. He also spent some time in Boston at the Dana Farber Cancer Institute and Harvard University. Over the years his principal clinical research interests have been in breast cancer, lung cancer and in new drug development. He has been involved in the early clinical development of several anti-cancer drugs which have subsequently proved effective in the clinic, including carboplatin, letrozole, mitozantrone and more recently Herceptin®. In the last decade he has become increasingly involved in neoadjuvant therapies and translational research. He is currently UK Principal Investigator for several international multi-center trials including HERA (Herceptin®), BIG1-98 (Letrozole) and ALTTO (Lapatinib), and he is international co-chair of the FACE trial (letrozole v anastrozole)
Professor Smith is Chairman of the newly formed UK Breast Trials Intergroup and Chairman of the British Breast Group. He has been past Chairman of several national professional bodies including the Association of Cancer Physicians, the Royal College of Physicians Specialist Advisory Committee for Medical Oncology, and the NCRI Lung Cancer Clinical Studies Group. He is currently a member of the NCRI Breast Cancer Study Group and is a member of numerous international cancer societies and pharmaceutical advisory boards. He is currently on the Scientific Review Committee for the San Antonio Breast Cancer Symposium and has published around 300 peer reviewed scientific papers, and lectures widely around the world.